Silo Pharma Gains European Patent for SPC-15 PTSD Therapy
SARASOTA, Fla., August 10, 2026 Silo Pharma, Inc. announced that the European Patent Office (EPO) has granted a patent...
PTSD
Advertisement
MAPS Responds to FDA Progress on MDMA-Assisted PTSD Therapy
Denver, Colorado, USA — August 10, 2026 Multidisciplinary Association for Psychedelic Studies (MAPS) responded to reports that Resilient Pharmaceuticals,...
Compass Pathways Partners with VA to Evaluate COMP360 for Treatment-Resistant Depression
LONDON & NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business...
Definium Therapeutics Advances DT120 ODT After Positive Phase 3 Results
NEW YORK, August 6, 2026 Definium Therapeutics reported its second quarter 2026 financial results and recent business highlights, led...
Silo Pharma Advances SPC-15 PTSD Program Toward FDA Meeting
SARASOTA, Fla., June 29, 2026 Silo Pharma announced that it has initiated a drug-device robustness study for SPC-15, its...
Advertisements
FDA Fast-Tracks Psychedelic Therapies for Mental Illness
WASHINGTON, D.C., April 24, 2026 The U.S. Food and Drug Administration has announced a series of accelerated regulatory actions...
Advertisement
